Progression and complications after external beam radiation therapy for carcinoma of prostate.
Sixty patients with prostatic carcinoma localized to the pelvis have been treated by external beam radiation therapy: 2 patients (2%) were Stage A, 12 (20%) Stage B, 14 (23%) Stage C, and 32 (53%) Stage D1. Twenty-two patients received adjuvant therapy (11 estramustine phosphate [Estracyt] and 11 cyclophosphamide [Cytoxan]) after radiation. Progression occurred in 22 patients (37%): 6 (10%) had local recurrence while 16 (27%) failed distally. The incidence of late major complications was 12 percent.
Brausi
M
M
Department of Urology, University of Tennessee, Memphis.
Soloway
M S
MS
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D011882:Radiotherapy, High-Energy / Q000009:adverse effects
D003037:Cobalt Radioisotopes; D004961:Estramustine; D003520:Cyclophosphamide